Ameliora Wealth Management Ltd. Takes $66,000 Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Ameliora Wealth Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 3,000 shares of the company’s stock, valued at approximately $66,000.

Other hedge funds also recently bought and sold shares of the company. UMB Bank n.a. grew its position in shares of Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares in the last quarter. Smithfield Trust Co raised its stake in Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Teva Pharmaceutical Industries in the third quarter valued at about $50,000. Claro Advisors LLC purchased a new stake in Teva Pharmaceutical Industries in the third quarter valued at about $52,000. Finally, Venturi Wealth Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the third quarter worth about $60,000. Institutional investors own 54.05% of the company’s stock.

Insider Activity

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on TEVA. UBS Group dropped their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. JPMorgan Chase & Co. lifted their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. StockNews.com downgraded Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, January 17th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.57.

Get Our Latest Stock Analysis on TEVA

Teva Pharmaceutical Industries Trading Up 0.6 %

TEVA opened at $17.31 on Friday. Teva Pharmaceutical Industries Limited has a one year low of $11.83 and a one year high of $22.80. The company has a market cap of $19.61 billion, a P/E ratio of -11.94, a PEG ratio of 1.43 and a beta of 0.71. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The business’s 50-day simple moving average is $20.03 and its 200-day simple moving average is $18.50.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last released its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 40.20% and a negative net margin of 9.91%. As a group, equities research analysts expect that Teva Pharmaceutical Industries Limited will post 2.62 EPS for the current fiscal year.

About Teva Pharmaceutical Industries

(Free Report)

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

See Also

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVAFree Report).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.